Mumbai, September 5 (Kiran News) — Shares of Zydus Lifesciences rose in Thursday’s session after its wholly owned subsidiary, Zydus Lifesciences Global FZE, signed an exclusive licensing and supply agreement with the Netherlands-based Synthon BV for the US market.
At 11:00 am, the stock was trading at ₹1,036.70, up 2.44% from its previous close of ₹1,012.00 on the BSE. The scrip opened at ₹1,023.00 and touched an intraday high of ₹1,039.00 and a low of ₹1,015.10. Around 36,373 shares were traded on the counter.
The BSE ‘A’ group stock, with a face value of ₹1, has a 52-week high of ₹1,135.95 (Sept 16, 2024) and a 52-week low of ₹797.05 (Apr 7, 2025). Its current market capitalisation stands at ₹1,03,999.31 crore. Promoters hold 74.99%, while institutional and non-institutional investors own 18.26% and 6.74% respectively.
The agreement covers Ozanimod Capsules (generic version of Zeposia), indicated for relapsing forms of multiple sclerosis. Synthon has a pending abbreviated new drug application (ANDA) with the US FDA. Under the deal, Synthon will secure final regulatory approvals, manufacture, and supply the product, while Zydus will handle commercialization in the United States.
As one of the first filers, Synthon has received tentative FDA approval within 30 months, making the product eligible for a shared 180-day exclusivity upon launch.
Zydus Lifesciences (formerly Cadila Healthcare) is an integrated pharmaceutical company engaged in the research, development, production, marketing, and distribution of pharmaceutical products.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
